Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18935995 | 0.93 | MEN1 (0.42) | MEN1KMT2AIDO1HRH3FAAH | |
| SCHEMBL106849 | 0.84 | SIGMAR1 (0.48) | IDO1HTR2ASIGMAR1 | |
| SCHEMBL196951 | 0.84 | IDO1 (0.67) | MEN1KMT2AIDO1HRH3LMNA | |
| SCHEMBL11917760 | 0.84 | MEN1 (0.49) | MEN1KMT2AIDO1HRH3LMNA | |
| SCHEMBL3438756 | 0.83 | IDO1 (0.52) | MEN1KMT2AIDO1HRH3LMNA | |
| SCHEMBL3269931 | 0.83 | TSHR (0.52) | IDO1HRH3 | |
| SCHEMBL648362 | 0.82 | MAOA (0.52) | SIGMAR1 | |
| Ammonia Solution, Strong SCHEMBL10647609 | 0.82 | SIGMAR1 (0.46) | IDO1HTR2ASIGMAR1 | |
| SCHEMBL3438749 | 0.81 | MEN1 (0.50) | MEN1KMT2AIDO1HRH3LMNA | |
| SCHEMBL8880401 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AIDO1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | LABORATORIOS ALMIRALL, S.A. (ES) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115826-A2 | Derivatives of 4-(2-Amino-1-Hydroxyethyl) Phenol as Agonists of the Beta2 AdrenergicReceptor | ADRB2, ADRB1, ADRA2C | MEN1 4796/4885KMT2A 2253/4885IDO1 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.